Mylan N.V. announced Wednesday the successful acquisition of the global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs, Inc.
The transaction provides Mylan all assets and rights relating to the Cold-EEZE brand, including all U.S. businesses and U.S. and international trademarks. The Cold-EEZE family of brands includes leading over-the-counter (OTC) cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the U.S.
Mylan CEO Heather Bresch commented, “The completion of this transaction is an important step as we continue to expand our consumer healthcare offerings. Cold-EEZE is now Mylan’s largest U.S. consumer healthcare brand and is part of a growing portfolio of over-the-counter products in the U.S. Mylan is committed to providing access to the medications that patients need, whether they are in front of or behind the pharmacy counter. We look forward to serving this loyal customer base and supporting this well-known brand.”
Mylan, a producer of active pharmaceutical ingredients, employs some 35,000 workers worldwide.
(Source: PR Newswire)
